Emerald Mutual Fund Advisers Trust Sells 154,973 Shares of Collegium Pharmaceutical, Inc. $COLL

Emerald Mutual Fund Advisers Trust trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 28.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 395,661 shares of the specialty pharmaceutical company’s stock after selling 154,973 shares during the quarter. Emerald Mutual Fund Advisers Trust owned 1.26% of Collegium Pharmaceutical worth $13,844,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Millennium Management LLC grew its stake in Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares during the period. Rubric Capital Management LP grew its position in Collegium Pharmaceutical by 5.3% during the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after buying an additional 157,743 shares during the period. Loomis Sayles & Co. L P grew its position in Collegium Pharmaceutical by 79.9% during the second quarter. Loomis Sayles & Co. L P now owns 337,137 shares of the specialty pharmaceutical company’s stock valued at $9,969,000 after buying an additional 149,766 shares during the period. Marshall Wace LLP purchased a new stake in Collegium Pharmaceutical during the second quarter worth about $4,043,000. Finally, Assenagon Asset Management S.A. raised its position in Collegium Pharmaceutical by 90.5% in the third quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company’s stock worth $6,844,000 after acquiring an additional 92,898 shares during the period.

Analyst Upgrades and Downgrades

COLL has been the subject of a number of research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Barclays reduced their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a report on Friday, January 9th. HC Wainwright restated a “buy” rating and issued a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Truist Financial set a $55.00 price target on Collegium Pharmaceutical in a research report on Wednesday, January 7th. Finally, Needham & Company LLC increased their price target on Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Collegium Pharmaceutical Stock Up 0.2%

Collegium Pharmaceutical stock opened at $47.10 on Friday. The firm has a 50 day simple moving average of $47.21 and a 200 day simple moving average of $39.53. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $50.79. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 29.25 and a beta of 0.60.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 EPS for the quarter, topping analysts’ consensus estimates of $1.89 by $0.36. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $209.36 million during the quarter, compared to analyst estimates of $191.25 million. During the same period last year, the company earned $1.61 earnings per share. The business’s revenue for the quarter was down 18.9% on a year-over-year basis. On average, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total value of $1,215,900.00. Following the completion of the transaction, the chief financial officer directly owned 126,667 shares in the company, valued at approximately $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This represents a 14.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 51,250 shares of company stock valued at $2,235,352 in the last quarter. 2.51% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.